STML-401-0423 A Phase II Multicenter Open-Label Trial of Tagraxofusp (TAG) in Combination with Venetoclax and Azacitadine (VEN/AZA) in Adults with Previously Untreated CD123+ Acute Myeloid Leukemia (AML) who are Ineligible for Intensive Chemotherapy